Gut Microbiota in Patients Receiving Dialysis: A Review

• Published in: Pathogens (Basel) Vol. 13; no. 9; p. 801
• Main Authors: Lim, Xintian, Ooi, Lijin, Ding, Uzhe, Wu, Henry H L, Chinnadurai, Rajkumar
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.09.2024; MDPI
• Subjects: Amino acids; Bacteria; chronic kidney disease; Chronic kidney failure; Composition; Context; Dialysis; Dietary restrictions; Digestive system; Dysbacteriosis; end-stage kidney disease; End-stage renal disease; Gastrointestinal system; Gastrointestinal tract; gut microbiota; Health aspects; Hemodialysis; Homeostasis; Immune system; Inflammation; Intestinal microflora; Kidney diseases; Kidney transplantation; Kidneys; Metabolism; Metabolites; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Mortality; Nutritional status; Patients; Peritoneal dialysis; Pharmaceuticals; Probiotics; Review; Systematic review; Toxins; Type 2 diabetes; dialysis; chronic kidney disease; end-stage kidney disease; gut microbiota
• ISSN: 2076-0817; 2076-0817
• DOI: 10.3390/pathogens13090801

The human gut microbiota constitutes a complex community of microorganisms residing within the gastrointestinal tract, encompassing a vast array of species that play crucial roles in health and disease. The disease processes involved in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are now increasingly established to result in dysregulation of gut microbiota composition and function. Gut microbiota dysbiosis has been associated with poor clinical outcomes and all-cause mortality in patients with ESKD, particularly individuals receiving dialysis. Prior studies highlighted various factors that affect gut microbiota dysbiosis in CKD and ESKD. These include, but are not limited to, uraemic toxin accumulation, chronic inflammation, immune dysfunction, medications, and dietary restrictions and nutritional status. There is a lack of studies at present that focus on the evaluation of gut microbiota dysbiosis in the context of dialysis. Knowledge on gut microbiota changes in this context is important for determining their impact on dialysis-specific and overall outcomes for this patient cohort. More importantly, evaluating gut microbiota composition can provide information into potential targets for therapeutic intervention. Identification of specific microbial signatures may result in further development of personalised treatments to improve patient outcomes and mitigate complications during dialysis. Optimising gut microbiota through various therapeutic approaches, including dietary adjustments, probiotics, prebiotics, medications, and faecal transplantation, have previously demonstrated potential in multiple medical conditions. It remains to be seen whether these therapeutic approaches are effective within the dialysis setting. Our review aims to evaluate evidence relating to alterations in the gut microbiota of patients undergoing dialysis. A growing body of evidence pointing to the complex yet significant relationship which surrounds gut microbiota and kidney health emphasises the importance of gut microbial balance to improve outcomes for individuals receiving dialysis.